share_log

Vertex Pharmaceuticals Announced Results From Its Phase 2 Study Of Suzetrigine For Painful Lumbosacral Radiculopathy, The Study Met Its Primary Endpoint With Statistically Significant And Clinically Meaningful Reduction In Pain On The Numeric Pain...

Benzinga ·  Dec 19 19:02

Vertex Pharmaceuticals Announced Results From Its Phase 2 Study Of Suzetrigine For Painful Lumbosacral Radiculopathy, The Study Met Its Primary Endpoint With Statistically Significant And Clinically Meaningful Reduction In Pain On The Numeric Pain Rating Scale

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment